Navigation Links
Pharmasset Reports Fiscal Second Quarter 2011 Financial Results
Date:4/25/2011

merase, thus inhibiting viral replication. We currently have three clinical-stage product candidates. PSI-7977, an unpartnered uracil nucleotide analog that is currently dosing in three Phase 2b studies in patients with HCV genotypes 1 through 6 and PSI-938, an unpartnered guanosine nucleotide analog which recently completed a 14-day monotherapy study and a 14-day combination study with PSI-7977. RG7128, a cytosine nucleoside analog for chronic HCV infection, is in two Phase 2b clinical studies in combination with Pegasys® plus Copegus® and one interferon free combination trial. These clinical studies are being conducted through a strategic collaboration with Roche.

Pegasys(R) and Copegus(R) are registered trademarks of Roche.

Forward-Looking StatementsPharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995:  Statements in this press release that are not historical facts are "forward-looking statements," that involve risks, uncertainties, and other important factors, including, without limitation,  the risk of cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates,  the risk that the results of previously conducted studies involving our product candidates will not be repeated or observed in ongoing or future studies involving our product candidates, the risk that our collaboration with Roche will not continue or will not be successful, and the risk that any one or more of our product candidates will not be successfully developed and commercialized.  For a discussion of risks, uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended September 30, 2010 and our Quarterly Reports on Form 10-Q filed with the Securities an
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
2. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
3. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
4. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
5. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
6. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
7. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
8. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
9. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
10. Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
11. Pharmasset Receives Notice of Allowance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... Bionomics Limited (ASX:BNO, ADR:BMICY), a biopharmaceutical company ... for the treatment of cancer and diseases of the ... from three of its most advanced oncology programs at ... th Annual Meeting being held from April 18-22, ... The presentation on the BNC105 program ...
(Date:4/16/2015)... WASHINGTON , April 16, 2015 Vanda ... company focused on the development and commercialization of products ... announced it will release results for the first quarter ... market closes. The Company will host ... May 6, 2015, during which Vanda management will discuss ...
(Date:4/16/2015)... WASHINGTON , April 16, 2015 A drug ... the eyesight of people with multiple sclerosis (MS), according to ... American Academy of Neurology,s 67th Annual Meeting in ... "About half of people with MS experience at ... neuritis, in which the nerve carrying vision from the eye ...
Breaking Medicine Technology:Bionomics Showcases Oncology Drug Development Programs at 2015 AACR Annual Meeting 2Bionomics Showcases Oncology Drug Development Programs at 2015 AACR Annual Meeting 3Bionomics Showcases Oncology Drug Development Programs at 2015 AACR Annual Meeting 4Bionomics Showcases Oncology Drug Development Programs at 2015 AACR Annual Meeting 5Vanda Pharmaceuticals to Announce First Quarter 2015 Financial Results on May 6, 2015 2Epilepsy Drug May Preserve Eyesight for People with MS 2
(Date:4/18/2015)... "I wanted to live a healthier ... juice that contained essential vitamins, minerals and nutrients," ... my energy, improves skin elasticity and gives me ... Juice to contain fruits, vegetables and other healthful ... mental fatigue. It features a great taste. The ...
(Date:4/18/2015)... 2015 Lowcostcarinsuranceprice.com has released a new ... on auto insurance prices . , Drivers ... vehicle theft may have to pay more for auto ... insurance policies can also offer protection against vehicle theft. ... compared online on a single website: http://lowcostcarinsuranceprice.com/ ...
(Date:4/18/2015)... 18, 2015 Thousand of DePuy Pinnacle ... of individuals who were allegedly harmed by a metal-on-metal ... forward in the U.S. District Court, Northern District of ... Court has amended an earlier Case Management Order to ... things, the new amendment permits the claims of up ...
(Date:4/18/2015)... (PRWEB) April 18, 2015 On April 14th, ... Threat Report , which they say, “exposes a tactical shift ... new malware variants were introduced in 2014 - almost a ... Zero Day threats to be identified and patched by prominent ... abundantly clear that doing business in a digital world can ...
(Date:4/18/2015)... PHOENIX, ARIZONA – In March, Mark ... other secure destruction professionals across the United States, earned ... will now display “CSDS” as a professional title with ... National Association of Information Destruction 2015 Annual Conference began ... Of the 20 people who took the exam, Ona ...
Breaking Medicine News(10 mins):Health News:High Rates Of Car Theft Can Have An Impact on Auto Insurance Prices! 2Health News:DePuy Pinnacle Hip Lawsuits: Federal Litigation Amends Case Management Order to Allow for Joinder of Unrelated Claims 2Health News:DePuy Pinnacle Hip Lawsuits: Federal Litigation Amends Case Management Order to Allow for Joinder of Unrelated Claims 3Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 2Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 3Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 4Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 5
... don't feel well prepared to make the decision to ... of life // , reports a study in the ... ,Nephrologists who are more experienced and more familiar ... the Renal Physicians Association and the American Society of ...
... containing rhubarb extract could minimize the severity of hot ... perimenopausal women to determine the usefulness of rhubarb extracts. ... extract, while the other half took a placebo for ... pill, had less severe hot flashes than the placebo ...
... new study says that drinking alcohol is linked to ... of drinking//. ,"Social drinking builds social capital," ... Jose State University. "Social drinkers are out networking, ... result in bigger paychecks." ,The researchers said that ...
... lung quality as part of the San Antonio Lung ... available donor lungs and transplant procedures without compromising recipient ... ,The study appears in the second issue for ... Critical Care Medicine, published by the American Thoracic Society. ...
... a further risk of further strokes if they suffer high ... strokes could also disable nearly 50% of the patients. , ... said” Stroke incidence and mortality are generally disproportionately higher among ... be explained by a greater vascular risk among African Americans.” ...
... key chemicals on the inner lining of the nose ... to the usual current treatments according// to researchers at ... million Americans know the misery of persistent inflammation of ... cavities. The result is clogged passages and recurring infections, ...
Cached Medicine News:Health News:Many Kidney Specialists Feel Unprepared for End-of-Life Decisions 2Health News:Upgrading Donor Lung Quality to Improve Availability 2Health News:Upgrading Donor Lung Quality to Improve Availability 3Health News:Chronic Sinusitis Resulting From Weakene Immune System 2Health News:Chronic Sinusitis Resulting From Weakene Immune System 3
Incontinence Pessaries...
Incontinence Pessaries...
HODGE with support designed for patient with limited pubic notch and mild cystocele. The folding HODGE Pessary with Support is indicated for the woman with stress urinary incontinence with a mild cyc...
Indications: for young women who experience stress urinary incontinence when excercising vigorously; i.e., aerobics, tennis, jogging....
Medicine Products: